Yazar "Berktas, Haci Bayram" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Effect of neuro-linguistic programming on COVID-19 fear in kidney transplant patients: A randomized controlled study
    (Elsevier Sci Ltd, 2022) Dogan, Aysel; Dogan, Runida; Menekli, Tugba; Berktas, Haci Bayram
    This study was conducted experimentally to evaluate the effect of neuro-linguistic programming (NLP) on fear of COVID-19 in kidney transplant patients. The study was carried out between June 2021 and October 2021. The Personal Information Form and COVID-19 Fear Scale (FCV-19S) were used to collect data. The obtained data obtained were evaluated using the SPSS 25 software. NLP was found to reduce the fear of COVID-19 in kidney transplant patients. Clinical nurses can use NLP techniques to support patients with fear in similar patient groups. Patients can be provided with access to training programs where they can learn NLP techniques. Clinicaltrials.gov: NCT05115435.
  • Küçük Resim
    Öğe
    Etodolac induced acute interstitial nephritis and autoimmune hemolytic anemia
    (2016) Berktas, Haci Bayram; Yiğit, İrem Pembegül; Taşkapan, Hülya; Akpolat, Nusret
    Abstract: In spite of the widespread use of non-steroidal anti-inflammatory drugs (NSAIDs) such as etodolac, induction of drug-dependent antibodies that cause hemolytic anemia and acute tubulointerstitiel nephritis are rarely reported. Currently, there is no way of identifying individuals who are at risk to develop this kind of complications. In patients who present with acute immune hemolysis and acute renal failure, it is important that a careful history of medication be obtained, potential sensitizing medications be identified. In this article we describe a patient with acute autoimmune hem olytic anemia and acute renal failure related with etodolac
  • Küçük Resim Yok
    Öğe
    The evaluation and classification of drug-related problems by a clinical pharmacist in an internal diseases intensive care unit: A prospective cohort 7-month study
    (Istanbul Univ, Fac Pharmacy, 2024) Durmus, Mefkuere; Gun, Zeynep Ulku; Berktas, Haci Bayram
    Background and Aims: Drug -related problems can cause morbidity and mortality as well as increase health-care costs. Clinical pharmacists provide many benefits to healthcare systems by detecting, decreasing, and preventing drug -related problems. It was aimed to determine and classify drug -related problems and determine risk factors for drug -related problems. Methods: Drug -related problems were evaluated prospectively between August 16, 2021, and March 16, 2022, in 257 patients during their hospital stay who were hospitalized in the internal diseases intensive care unit and took at least one drug. Patients who were not administered any drug or who were younger than 18 were excluded from the study. The Pharmacetical Care Network Europe v.9 method was utilized to classify these problems. Clinical and demographic characteristics of patients with and without drug -related problems were compared by statistical analysis. Risk factors of drug -related problems were determined by logistic regression analysis. Results: At least one drug -related problem was detected in 157 of the 257 patients and a total of 399 drug -related problems were recorded. 399 recommendations were made, and 349 (87.5%) of these were accepted and 50 (12.5%) were not accepted. Drug selection (C1) was the most common cause of drug -related problems at 42.2%, and dose selection (C3) followed this by 41.5%. The results of regression analysis showed that atrial fibrillation (OR: 2.985, CI: 1.158-7.692), hematopoietic stem cell transplantation (OR: 3.883, CI: 1.256-11.999), antibacterial drugs (OR: 3.285, CI: 1.563-6.904), or polypharmacy (OR: 3.955, CI:1.207- 11.071) were risk factors of drug -related problems. Conclusion: The most common drug -related problem category was found as treatment safety and the causes of them were found as drug selection and dose selection. Clinicians should pay attention when prescribing new drugs to patients with atrial fibrillation and a history of hematopoietic stem cell transplantation. Furthermore, clinicians and clinical pharmacists should pay attention if polypharmacy and antibacterial drugs are present in medical therapies.
  • Küçük Resim Yok
    Öğe
    A life-saving therapy in Class I HELLP syndrome: Therapeutic plasma exchange
    (Pergamon-Elsevier Science Ltd, 2015) Erkurt, Mehmet Ali; Berber, Ilhami; Berktas, Haci Bayram; Kuku, Irfan; Kaya, Emin; Koroglu, Mustafa; Nizam, Ilknur
    HELLP syndrome, which can affect multiple organ systems and cause maternal and fetal mortality, is a serious complication of pregnancy characterized by microangiopathic hemolytic anemia, elevation of liver enzymes, and thrombocytopenia. Delivering the infant usually suffices for the treatment of this syndrome. In cases with Class I HELLP syndrome, however, the clinical picture may rapidly deteriorate despite delivery. In this paper we presented the outcomes with the use of therapeutic plasma exchange in cases with class I HELLP syndrome. This study included 21 patients diagnosed with the Class I HELLP syndrome at Inonu University Faculty of Medicine, Department of Hematology between 2011 and 2014. A central venous catheter was placed and plasma exchange therapy was begun in patients unresponsive to delivery, steroid, and supportive therapy (blood and blood products, antihypertensive therapy, intravenous fluid administration, and antibiotics) within 24 hours after the diagnosis of Class I HELLP syndrome according to the Mississippi Criteria. All patients underwent therapeutic plasma exchange for three sessions each with a 1:1 volume. Hemogram and biochemical parameters of the patients were evaluated before and after the procedure. According to results, there was a statistically significant decrease in total bilirubin, LDH, AST, and ALT levels whereas a significant increase in platelet count was observed. Hemoglobin levels were increased, although this increase was not statistically significant. HELLP syndrome is primarily treated with the delivery of infant; however, some cases may show disease progression despite completion of delivery. As a potential cause of both maternal and fetal mortality, HELLP syndrome condition should be aggressively treated. Therapeutic plasma exchange is one of the available treatment options. Our study has found that postpartum use of plasma exchange therapy within 24 hours is an efficient and lifesaving treatment choice in Class I HELLP syndrome. (C) 2014 Elsevier Ltd. All rights reserved.